Meeting
2017 Genitourinary Cancers Symposium
A phase 1 study of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients with metastatic renal cell cancer.
Authors
Hans J. Hammers
University of Texas Southwestern Medical Center
Hans J. Hammers , Charles G. Drake , Yousef Zakharia , Eugene Paul Kennedy , Nicholas N. Vahanian , Charles J. Link , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT02035358
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 528)
DOI
10.1200/JCO.2017.35.6_suppl.528
Abstract #
528
Poster Bd #
G22
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Final results of a phase I trial of HERV-E TCR transduced T cells for the treatment of HLA-A*11 patients with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Rosa Nadal
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.
First Author: Wen Wee Ma
First Author: Paolo Strati